Want to see LXRX full AI Analyst Report?
Top Page
Lexicon Pharmaceuticals
(NASDAQ:LXRX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$2.50
▲(9.17% Upside)
Action:Reiterated
Date:08/07/26
The score is held back primarily by weak financial performance (ongoing losses, cash burn, and recent revenue decline), partially offset by a strengthened balance sheet (no debt) and a constructive earnings-call outlook driven by late-stage pipeline/regulatory milestones and improved liquidity. Technicals add support with the stock trading above major moving averages, while valuation is not supportive given negative earnings and no dividend.
Positive Factors
Strengthened liquidity & balance sheet
Materially higher cash and a new credit facility extend runway and give management flexibility to fund late-stage trials, precommercial investments, and milestone needs without immediate dilution. This improves financial optionality and lowers near-term insolvency risk during regulatory execution.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow (~-$80M TTM) indicates the company is consuming cash to fund development and operations. Continued burn increases dependence on external financing, heightens dilution risk or covenant pressure, and could constrain investment if additional capital is delayed or terms worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened liquidity & balance sheet
Materially higher cash and a new credit facility extend runway and give management flexibility to fund late-stage trials, precommercial investments, and milestone needs without immediate dilution. This improves financial optionality and lowers near-term insolvency risk during regulatory execution.
Read all positive factors
Lexicon Pharmaceuticals (LXRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)4.03M
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-29.03%
EPS Growth54.11%
CountryUS
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding444,955,930
10 Day Avg. Volume2,625,675
30 Day Avg. Volume4,028,280
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside162.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$37.94M
Lexicon Pharmaceuticals Business Overview & Revenue Model
Company Description
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule dr...
How the Company Makes Money
Lexicon generates revenue primarily through (1) collaboration and licensing arrangements and (2) sales of products where it participates in commercialization, along with other related payments tied to its intellectual property. Under partnership d...
Lexicon Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.Positive Updates
Completion and Over-enrollment of SONATA-HCM Phase III
Completed enrollment in SONATA-HCM (largest Phase III in obstructive and nonobstructive HCM) with significant over-enrollment, improving study power; primary endpoint is change in KCCQ Clinical Summary Score at week 26; top-line data expected in Q1 2027.
Negative Updates
Sharp Revenue Decline Year-over-Year
Total revenues fell to $0.7 million in Q2 2026 from $28.9 million in Q2 2025, a decrease of approximately 97.6%, driven by absence of the $27.5 million licensing revenue recognized in Q2 2025 (previous Novo license recognition).
Read all updates
Q2-2026 Updates
Positive
Negative
Completion and Over-enrollment of SONATA-HCM Phase III
Completed enrollment in SONATA-HCM (largest Phase III in obstructive and nonobstructive HCM) with significant over-enrollment, improving study power; primary endpoint is change in KCCQ Clinical Summary Score at week 26; top-line data expected in Q1 2027.
Read all positive updates
Company Guidance
Management reiterated 2026 financial guidance and provided several key metrics: Q2 2026 revenue was $0.7M (vs. $28.9M in Q2 2025, which included $27.5M of Novo licensing revenue); R&D expense was $17.4M (vs. $15.7M), SG&A was $9.8M (vs. $9.4M); net loss was $31.8M, or $0.07 per share (vs. net income $3.3M, $0.01 per share), which included noncash stock‑based compensation of $3.3M (vs. $3.2M) and a $4.3M loss on early extinguishment of debt ($0.01 per share). Cash, cash equivalents and short‑term investments totaled $190.6M as of June 30, 2026 (up from $125.2M at Dec. 31, 2025). The company reiterated 2026 operating expense guidance of $100–110M, with R&D of $63–68M and SG&A of $37–42M; noted a $100M Hercules debt facility announced in May with a $55M initial tranche funded (used to repay Oxford), and additional $20M and $25M tranches available subject to milestones/consent, with an 18‑month interest‑only period and two possible 6‑month extensions. Timing and milestones highlighted: SONATA‑HCM top‑line expected Q1 2027; STENO1 exposure for the Zynquista NDA expected by end of August with a planned NDA resubmission in Q4 2026 (end‑October target) and possible regulatory action in mid‑2027; LX9851 has triggered two $10M Novo milestones to date with a potential third $10M later this year; and targeted precommercial investments in medical education, marketing and market access were initiated in Q2.Lexicon Pharmaceuticals Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.47M | 49.80M | 31.08M | 1.20M | 139.00K | 298.00K |
| Gross Profit | 40.99M | 49.53M | 30.46M | -57.77M | -52.38M | -54.75M |
| EBITDA | -52.25M | -41.38M | -184.29M | -169.76M | -100.03M | -86.66M |
| Net Income | -61.12M | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M |
Balance Sheet | ||||||
| Total Assets | 250.06M | 184.99M | 298.42M | 229.43M | 194.30M | 136.91M |
| Cash, Cash Equivalents and Short-Term Investments | 190.61M | 96.23M | 237.96M | 170.03M | 138.36M | 86.74M |
| Total Debt | 59.28M | 62.24M | 108.40M | 106.06M | 55.29M | 2.28M |
| Total Liabilities | 75.53M | 77.45M | 152.47M | 136.32M | 77.17M | 23.31M |
| Stockholders Equity | 174.53M | 107.54M | 145.95M | 93.11M | 117.12M | 113.59M |
Cash Flow | ||||||
| Free Cash Flow | -79.72M | -67.85M | -179.81M | -162.37M | -90.18M | -88.24M |
| Operating Cash Flow | -79.72M | -67.85M | -178.78M | -161.90M | -88.85M | -87.02M |
| Investing Cash Flow | -100.03M | 113.02M | -15.38M | -49.94M | -71.08M | 2.11M |
| Financing Cash Flow | 174.07M | -48.50M | 238.35M | 187.96M | 142.21M | 22.71M |
Lexicon Pharmaceuticals Technical Analysis
Positive
2.29
Price Trends
2.23
Positive
2.04
Positive
1.71
Positive
Market Momentum
0.04
Positive
50.76
Neutral
73.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXRX, the sentiment is Positive. The current price of 2.29 is below the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.23, and above the 200-day MA of 1.71, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 73.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LXRX.
Lexicon Pharmaceuticals Risk Analysis
Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexicon Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $782.13M | 2.31 | 96.49% | ― | 3.31% | 221.64% | |
56 Neutral | $1.05B | -15.56 | -40.40% | ― | -29.03% | 54.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $720.20M | -2.81 | -220.07% | ― | 12.00% | -9.21% | |
50 Neutral | $283.45M | -1.46 | -33.22% | ― | 215.59% | 22.48% | |
48 Neutral | $475.38M | -10.94 | -14.98% | ― | 427.32% | 85.31% |
* Healthcare Sector Average
LXRX
Lexicon Pharmaceuticals
2.34
1.10
88.71%
RIGL
Rigel
40.79
1.28
3.24%
PRTA
Prothena
9.08
0.83
10.06%
RGNX
RegenXBio
10.66
1.84
20.86%
BCYC
Bicycle Therapeutics
3.98
-3.46
-46.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.